

How to Access AI Medical Diagnosis Tools: A Guide for Professionals and the Public

Rasit Dinc

Rasit Dinc Digital Health & AI Research

Published: November 13, 2023 | Medical Imaging AI

DOI: [10.5281/zenodo.17997311](https://doi.org/10.5281/zenodo.17997311)

Abstract

The integration of Artificial Intelligence (AI) into medicine represents a paradigm shift in healthcare delivery, particularly in the field of diagnostics. AI...

The integration of Artificial Intelligence (AI) into medicine represents a paradigm shift in healthcare delivery, particularly in the field of diagnostics. AI-enabled medical devices, often utilizing machine learning (ML) algorithms, are demonstrating remarkable potential in analyzing complex data—such as medical images, genetic sequences, and electronic health records—to assist in the early and accurate detection of diseases [1]. This technological leap promises to enhance diagnostic speed and accuracy, ultimately improving patient outcomes across various medical disciplines. As these technologies mature, the fundamental question for both practitioners and the public becomes: **How does one access AI medical diagnosis tools?** The answer is bifurcated, depending heavily on whether the user is a healthcare professional operating within a regulated clinical environment or a member of the general public seeking informational support.

Access for Healthcare Professionals: Institutional Integration

For healthcare professionals (HCPs), access to advanced AI diagnostic tools is primarily managed through **institutional integration** within established clinical workflows. These tools are typically deployed as Software as a Medical Device (SaMD) and are integrated directly into hospital systems, such as Picture Archiving and Communication Systems (PACS) for radiology, or Electronic Medical Records (EMRs) [2].

These systems are designed to augment the capabilities of clinicians, not replace them. For instance, platforms like Viz.ai use AI algorithms to analyze medical imaging data, such as CT scans, to rapidly detect conditions like stroke or pulmonary embolism, alerting specialists within minutes [3]. Similarly, companies like Nanox AI (formerly Zebra Medical Vision) have developed FDA-cleared AI tools that assist radiologists in identifying critical findings in imaging studies [4]. Access, in this context, is governed by

institutional policy, regulatory compliance, and the need for specialized training to ensure the responsible and effective use of the technology. The procurement and deployment of these tools require a deep understanding of clinical validation, data security, and ethical implementation. Furthermore, the successful adoption of these technologies hinges on comprehensive training for clinical staff to interpret AI-generated insights correctly and integrate them seamlessly into patient care protocols.

For more in-depth analysis on the clinical integration and ethical deployment of these advanced tools, the resources at [www.rasitdinc.com] (<https://www.rasitdinc.com>) provide expert commentary and professional insight.

Access for the General Public: Decision Support and Symptom Checkers

The general public's access to AI diagnostic tools is more direct but fundamentally different in scope and purpose. Direct-to-consumer (DTC) applications and platforms are widely available, often taking the form of AI-powered symptom checkers or diagnostic decision support tools.

Tools such as DxGPT, which is based on large language models, and OpenEvidence, a medical information platform, offer users the ability to input symptoms or queries to receive potential differential diagnoses and relevant medical information [5] [6]. These tools are invaluable for health literacy and guiding users toward appropriate care pathways. However, a critical distinction must be made: these public-facing tools are generally classified as **informational or decision support systems**, and they are not intended to provide a definitive medical diagnosis. They lack the necessary clinical context, high-resolution medical data, and regulatory oversight required for a final diagnosis, which must remain the responsibility of a licensed HCP [7].

The Regulatory and Safety Landscape

The most crucial factor governing access to AI medical diagnosis tools is the regulatory framework, particularly in the United States, where the Food and Drug Administration (FDA) plays a central role. The FDA maintains a clear distinction between AI tools intended for informational purposes and those classified as medical devices.

AI/ML-enabled medical devices that are intended to diagnose, treat, mitigate, or prevent a disease are subject to rigorous review and must receive **FDA clearance or approval** before they can be legally marketed and used in clinical settings [8]. This regulatory process ensures the safety, effectiveness, and clinical validity of the algorithms. The FDA's publicly available list of authorized AI/ML-enabled medical devices serves as the definitive resource for professionals seeking to verify the clinical utility and regulatory status of a tool [9]. This stringent oversight is what separates the clinically validated tools used by HCPs from the general-purpose health apps available to the public. This regulatory clarity is vital for building trust in AI diagnostics among both the medical community and patients, ensuring that innovation does not compromise safety.

Access Pathway Target Audience Typical Function Regulatory Status :-
-- :-- :-- :-- Institutional/Clinical Healthcare Professionals Diagnostic Aid, Triage, Workflow Optimization Requires FDA Clearance/Approval (SaMD) Direct-to-Consumer General Public Symptom Checking, Health Information, Decision Support Generally Informational (Lower Regulatory Burden)

Conclusion

Accessing AI medical diagnosis tools depends on one's role in the healthcare ecosystem. For professionals, access is institutional, integrated, and strictly regulated, focusing on validated tools that enhance clinical accuracy and efficiency. For the public, access is direct and informational, providing valuable decision support but requiring the ultimate validation of a human physician. As AI continues to transform diagnostics, understanding this dual access structure and the underlying regulatory safeguards is essential for navigating the future of digital health.

**

References

- [1] Alowais, S. A. (2023). *Revolutionizing healthcare: the role of artificial intelligence in medical education*. BMC Medical Education. [URL: <https://bmcmmededuc.biomedcentral.com/articles/10.1186/s12909-023-04698-z>]
- [2] AMA. (2024). *Using AI in diagnosis means scrutinizing each tool. Here's how*. American Medical Association. [URL: <https://www.ama-assn.org/practice-management/digital-health/using-ai-diagnosis-means-scrutinizing-each-tool-here-s-how>]
- [3] Viz.ai. (n.d.). The proven AI-powered care coordination platform. [URL: <https://www.viz.ai/>]
- [4] Medicaï. (2025). *Top 10 AI Diagnosis Vendors: Revolutionizing Healthcare*. Medicaï Blog. [URL: <https://blog.medicaï.io/en/ai-diagnosis-vendors/>]
- [5] DxGPT. (n.d.). Diagnostic decision support software. [URL: <https://dxgpt.app/>]
- [6] OpenEvidence. (n.d.). The leading medical information platform. [URL: <https://www.openevidence.com/>]
- [7] Hajiheydari, N. (2025). *AI in medical diagnosis: A contextualised study of patient responses*. Social Science & Medicine. [URL: <https://www.sciencedirect.com/science/article/pii/S0277953625001790>]
- [8] FDA. (n.d.). *Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices*. U.S. Food and Drug Administration. [URL: <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices>]
- [9] FDA. (2025). *Artificial Intelligence-Enabled Medical Devices*. U.S. Food and Drug Administration*. [URL: <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices>]

